Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from MaxCyte ( (MXCT) ) is now available.
MaxCyte, Inc. has announced a change in its major holdings, with BlackRock, Inc. crossing a threshold in its voting rights. BlackRock now holds a total of 7.70% of voting rights in MaxCyte, a slight decrease from its previous position. This change in holdings may impact MaxCyte’s shareholder dynamics and influence future corporate decisions.
More about MaxCyte
MaxCyte, Inc. operates in the biotechnology industry, focusing on providing cell-engineering platform technologies. The company is known for its proprietary flow electroporation technology, which is used in cell-based research and development, particularly in the fields of gene editing and cell therapy.
YTD Price Performance: -40.74%
Average Trading Volume: 30,654
Technical Sentiment Signal: Buy
Current Market Cap: £209.2M
For a thorough assessment of MXCT stock, go to TipRanks’ Stock Analysis page.